In addition to PTT, AuNPs have been used in testing as precise delivery systems for immune checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 antibodies, which enhance tumor selectivity and lower systemic toxicity [88]. This evidence concerns the gene CTLA4 and neoplasm.